Miss Yue Lan
Alzheimer’s Disease (AD), an incurable neurodegenerative disorder is characterized by irreversible deposition of amyloid plaques and fibrillary tangles as well as progressive memory and cognitive decline. Amyloid-𝛃 (A𝛃) peptides, Tau, and neurofilament light (NfL) proteins in cerebral spinal fluid (CSF) are considered useful biomarkers for AD1. Numerous studies have shown that soluble A𝛃42 oligomers are more neurotoxic and also be found in circulatory body fluids2, 3. The conventional enzyme-linked immunosorbent assay (ELISA) is a widely adopted for quantification the AD biomarkers including A𝛃 oligomers. However, the sensitivity of ELISA is not satisfactory for the detection of low-abundance of such biomarkers in the early stage of AD. In this work, we have developed an ultrasensitive, cost-efficient, and reliable method for the quantification of A𝛃42 oligomers in a few µL body fluids (CSF and serum). This assay is based on a specific antibody-antigen immunoreaction and formation of immuno-sandwich complexes on magnetic nanoparticles followed by labeling of the target protein with a tailor-made cyanine-based turn-on fluorophore, named SPM. Our initial results demonstrated that the detection limit of the sensitive assay reached 10-3 ng/mL. This assay holds great potential for diagnosing AD at the early stage.
- Jamerlan, A.; An, S. S. A.; Hulme, J. TrAC Trends in Analytical Chemistry 2020, 129, 115919.
- Ahmed, M., Davis, J., Aucoin, D. et al. Nature Structural & Molecular Biology 2010, 17 (5), 8.
- Cizas, P.; Budvytyte, R.; Morkuniene, R.; Moldovan, R.; Broccio, M.; Lösche, M.; Niaura, G.; Valincius, G.; Borutaite, V. Archives of Biochemistry and Biophysics 2010, 496 (2), 84–92.